Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Sullivan, Keith M., Mitchell Horwitz, Ifeyinwa Osunkwo, Nirmish Shah, and John J. Strouse. “Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease..” Biol Blood Marrow Transplant 24, no. 5 (May 2018): 883–84. https://doi.org/10.1016/j.bbmt.2018.04.001.

PMID
29649619
Full Text

Sung, Anthony D., Syed Hassan, Diana M. Cardona, Daniel Wild, Krista Rowe Nichols, Hossein Mehdikhani, Bryan Balmadrid, et al. “Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults..” Biol Blood Marrow Transplant 24, no. 4 (April 2018): 734–40. https://doi.org/10.1016/j.bbmt.2017.12.772.

PMID
29246821
Full Text

Somers, Tamara J., Sarah A. Kelleher, Caroline S. Dorfman, Rebecca A. Shelby, Hannah M. Fisher, Krista Rowe Nichols, Keith M. Sullivan, et al. “An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial..” Jmir Mhealth Uhealth 6, no. 3 (March 19, 2018). https://doi.org/10.2196/mhealth.8565.

PMID
29555620
Full Text

Sullivan, Keith M., Ellen A. Goldmuntz, and Daniel E. Furst. “Autologous Stem-Cell Transplantation for Severe Scleroderma..” N Engl J Med 378, no. 11 (March 15, 2018): 1066–67. https://doi.org/10.1056/NEJMc1801275.

PMID
29539292
Full Text

Sullivan, Keith M., Ellen A. Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, et al. “Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma..” N Engl J Med 378, no. 1 (January 4, 2018): 35–47. https://doi.org/10.1056/nejmoa1703327.

PMID
29298160
Full Text

Sivaraj, D., W. Bacon, G. D. Long, D. A. Rizzieri, M. E. Horwitz, K. M. Sullivan, Y. Kang, Z. Li, N. J. Chao, and C. Gasparetto. “High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma..” Bone Marrow Transplant 53, no. 1 (January 2018): 34–38. https://doi.org/10.1038/bmt.2017.208.

PMID
29084203
Full Text

Huang, Li-Wen, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M. Sullivan, et al. “Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma..” Hematol Oncol 35, no. 4 (December 2017): 752–59. https://doi.org/10.1002/hon.2379.

PMID
28105753
Full Text

Arnold, Staci D., Ruta Brazauskas, Naya He, Yimei Li, Richard Aplenc, Zhezhen Jin, Matt Hall, et al. “Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases..” Haematologica 102, no. 11 (November 2017): 1823–32. https://doi.org/10.3324/haematol.2017.169581.

PMID
28818869
Full Text

Anand, Sarah, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Gwynn D. Long, Richard Lopez, Ashley K. Morris, et al. “Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning..” In Biol Blood Marrow Transplant, 23:1949–54, 2017. https://doi.org/10.1016/j.bbmt.2017.06.027.

PMID
28729147
Full Text

Keever-Taylor, Carolyn A., Shelly Heimfeld, Kaitlyn C. Steinmiller, Richard A. Nash, Keith M. Sullivan, Christine W. Czarniecki, Tomeka C. Granderson, Julia S. Goldstein, and Linda M. Griffith. “Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases..” Biol Blood Marrow Transplant 23, no. 9 (September 2017): 1463–72. https://doi.org/10.1016/j.bbmt.2017.05.018.

PMID
28602891
Full Text

Pages